Rheumatology Network Newsletter

To view this email as a web page, click here.

Nintedanib Shows Efficacy for Systemic Sclerosis Lung Disease

Patients with systemic sclerosis-associated interstitial lung disease who also take nintedanib experience a lower drop in their forced vital capacity, according to a new study.

Etanercept Trial Supports Use for JIA, ERA, and PsA

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

PsA Quiz: Can you identify the appropriate treatment for newly diagnosed patients?

In round two of our ongoing psoriatic arthritis quiz series, we focus on treatment recommendations made in the 2018 ACR/NPF psoriatic arthritis treatment guidelines. We also include a puzzler based on findings from a newly published study.

FDA Rheumatology Drug Approvals: Pediatric lupus, spondyloarthritis and more

From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.

Early SLE often Misdiagnosed for Mimics

Patients with systemic lupus erythematosus often have a range of clinical symptoms that are nonspecific and overlap with other medical conditions, such as Sjögren’s syndrome, rheumatoid arthritis and Raynaud's syndrome.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.